Q2 2026 Cytek Biosciences Inc Earnings Call Transcript
Key Points
- Cytek Biosciences Inc (CTKB) delivered solid Q2 2026 revenue growth of 6% year-over-year, reaching $48.1 million, driven by strong double-digit growth in the US and China.
- The company's high-end FSP instrument portfolio grew 11% year-over-year, led by strong sales of the Aurora Evo Analyzer and Aurora CS systems.
- Cytek Biosciences Inc (CTKB) launched the Borealis, the industry's first 60-color, seven-laser full spectral flow cytometer, which has received very strong feedback from early access customers.
- The recurring revenue base (reagents and services) strengthened, growing 8% year-over-year to $18.5 million and now representing 35% of last 12-month revenue, up from 32% in the prior year period.
- The company raised the low end of its full-year 2026 revenue guidance to $207 million-$212 million, reflecting positive year-to-date results and a strong growth outlook, particularly in the US and APAC.
- Cytek Biosciences Inc (CTKB) maintains a strong balance sheet with $262 million in cash and marketable securities, providing financial flexibility for investment in growth priorities.
- Cytek Biosciences Inc (CTKB) experienced continued softness in EMEA, with revenue down approximately 8% year-over-year due to ongoing government budgetary pressures from regional geopolitical dynamics.
- Total APAC revenue, excluding China, was flat year-over-year, with softness in other parts of the region offsetting strong growth in China.
- GAAP net loss widened to $12.2 million in Q2 2026 from $5.6 million in the prior year quarter, impacted by higher operating losses, foreign exchange losses, and a non-recurring investment write-off.
- Adjusted EBITDA turned negative at a loss of $1.5 million in Q2 2026, compared to a positive $1.3 million in Q2 2025, due to higher operating expenses and lower investment income.
- Academic and government revenue declined 12% year-over-year to $19.1 million, as strong US growth was offset by weakness in EMEA and other APAC regions.
- The company's strategic reorganization into three business units is expected to take time to yield significant benefits, with the full impact on growth not expected to materialize immediately.
Hello, and thank you for standing by. My name is Lacey, and I will be your conference operator today. At this time, I would like to welcome everyone to the CyTech Biosciences Second Quarter 2026 Earnings Conference Call.
All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. To withdraw your question, press star one again. Thank you. I would now like to turn the call over to Mark Meehan. Please go ahead.
Thank you, operator. Joining me today from SciTech are Win Bin Jung, CEO and Bill McCoom, CFO. Earlier today, SciTech Biosciences released financial results for the second quarter ended June 30, 2026. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an email to [email protected].
A copy of the news
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
